SAN DIEGO--(BUSINESS WIRE)--Mirador Therapeutics, Inc. (Mirador) announced its launch today. Founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for $10.8 billion), Mirador aims to revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases by leveraging its proprietary Mirador360TM development engine to rapidly advance multiple programs.

圣地亚哥--（商业新闻短讯）--Mirador Therapeutics，Inc.（Mirador）今天宣布推出。Mirador由Mark C.McKenna创立，由普罗米修斯生物科学公司（Prometheus Biosciences）（2023年被默克以108亿美元收购）的几位前高管领导，旨在通过利用其专有的Mirador360TM开发引擎快速推进多个项目，彻底改变免疫介导的炎症和纤维化疾病的精准医学。

Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also participated, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments..

米拉多在ARCH Venture Partners的带领下，通过OrbiMed和Fairmount的早期投资，筹集了4亿多美元的资金。其他卓越的生命科学投资者也参加了会议，包括Fidelity Management&Research Company、Point72、Farallon Capital Management、Boxer Capital、TCGX、Invus、Logos Capital、Moore Strategic Ventures、Blue Owl Healthcare Opportunities、赛诺菲Ventures、Woodline Partners LP、Venrock Healthcare Capital Partners、RTW Investments和Alexandria Venture Investment。

“At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador. “The industry has only scratched the surface of utilizing advances in human genetics – coupled with exponential progress in machine learning – to accelerate the development of precision therapies for patients who need them the most.

Mirador董事长兼首席执行官马克·麦肯纳（Mark C.McKenna）表示：“在Mirador，我们设想了一个大胆的精准医学新时代，以速度和卓越的开发准确性为驱动力，治疗免疫介导的炎症和纤维化疾病。”“利用人类遗传学的进步，再加上机器学习的指数级进步，加速为最需要精确疗法的患者开发精确疗法，这一行业只触及了表面。

With a proven team, distinguished board of directors, leading healthcare investors and proprietary data-driven approach, we aim to create a leading precision medicine company at scale to provide important new treatment options for patients.”.

凭借一支经过验证的团队、杰出的董事会、领先的医疗保健投资者和专有的数据驱动方法，我们的目标是创建一家规模领先的精准医学公司，为患者提供重要的新治疗选择。”

“The I&I field is in need of better, novel therapeutics as well as new R&D approaches that target enriched patient populations for improved probability of success in the clinic,” said Kristina Burow, Mirador board member and managing director of ARCH Venture Partners. “The Mirador team has an outstanding track record of success in precision immunology, and we are well on our way to building a company that will make a lasting impact on the lives of millions of patients suffering from a broad range of immune-mediated inflammatory and fibrotic diseases.”.

米拉多董事会成员兼ARCH Venture Partners董事总经理克里斯蒂娜·伯罗（KristinaBurow）表示：“I＆I领域需要更好、新颖的治疗方法以及针对丰富患者群体的新研发方法，以提高临床成功的可能性。”。“Mirador团队在精准免疫学方面取得了出色的成功，我们正在努力建立一家公司，这将对数百万患有多种免疫介导的炎症和纤维化疾病的患者的生活产生持久影响。”

The Next Wave of Precision Medicine in Immunology and Inflammation (I&I)

免疫学和炎症领域的下一波精准医学（I＆I）

Mirador’s focus is on developing first-in-class or best-in-class precision medicines. To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science. Mirador360 is purpose-built to harmonize millions of patient molecular profiles to discover and validate genetic associations to immuno-fibrotic diseases, identify novel therapeutic targets and elucidate target-target interactions as well as optimal target-target pairs for potential combination therapies.

米拉多的重点是开发一流或一流的精准药物。为了加速开发，Mirador使用了Mirador360，这是其专有的精确开发引擎，它利用了人类遗传学和尖端数据科学的最新突破。Mirador360旨在协调数百万患者的分子谱，以发现和验证与免疫纤维化疾病的遗传关联，确定新的治疗靶点，阐明靶-靶相互作用以及潜在联合治疗的最佳靶-靶对。

Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development..

Mirador360还允许Mirador开发诊断并对异质患者人群进行分层，以实现精确的临床开发。

About Mirador Therapeutics

关于Mirador Therapeutics

Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.

Mirador是一家专注于免疫学和炎症的下一代精准医学公司。该公司的Mirador360 TM精密开发引擎利用人类遗传学和尖端数据科学的最新进展，为患有慢性免疫介导的炎症和纤维化疾病的患者快速开发新的精密药物。

Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.

Mirador成立于2024年，已从领先的生命科学投资者那里筹集了4亿多美元资金，总部位于加利福尼亚州圣地亚哥。